| 引用本文: | 朱延焱,楼建,谢艳茹,张霞燕,田伟强.1例吉非替尼与华法林相互作用的案例报道及文献分析[J].中国现代应用药学,2019,36(11):1395-1398. |
| ZHU Yanyan,LOU Jian,XIE Yanru,ZHANG Xiayan,TIAN Weiqiang.Drug Interaction Induced by Warfarin and Gefitinib: A Case Report and Review of the Literature[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(11):1395-1398. |
|
| 摘要: |
| 目的 结合实际案例，对吉非替尼与华法林联用时华法林的剂量调整进行文献检索和分析，为给药方案的优化提供参考。方法 报道1例病例，同时查阅国内外相关文献并进行综述分析。结果 本例患者在合并使用吉非替尼26 d后，INR值明显升高（5.23），停药后调整华法林剂量，将INR值控制在目标范围内。文献综述分析提示，吉非替尼及表皮生长因子受体酪氨酸激酶抑制剂与华法林联用时，有一部分人群可能会出现INR值升高，出血风险增加。结论 华法林和表皮生长因子受体酪氨酸激酶抑制剂联合使用时，建议在启用以及停药后，增加INR的监测频率，及时调整华法林剂量。 |
| 关键词: 吉非替尼 华法林 表皮生长因子受体酪氨酸激酶抑制剂 INR 相互作用 |
| DOI：10.13748/j.cnki.issn1007-7693.2019.11.017 |
| 分类号:R969.3 |
| 基金项目:丽水市科技计划项目（2016GYX40） |
|
| Drug Interaction Induced by Warfarin and Gefitinib: A Case Report and Review of the Literature |
|
ZHU Yanyan1, LOU Jian2, XIE Yanru2, ZHANG Xiayan1, TIAN Weiqiang1
|
|
1.Pharmacy Department, Lishui Municipal Central Hospital, Lishui 323500, China;2.Oncology Department, Lishui Municipal Central Hospital, Lishui 323500, China
|
| Abstract: |
| OBJECTIVE To report an actual case and review about the interaction of warfarin and gefitinib to provide a regimen about the combination of the two drugs. METHODS Discribed a case and analyzed it,while access to relevant literature review. RESULTS With concomitant administration of gefitinib and warfarin, 26 d later the patient's INR values increased to 5.23, then discontinue the two drugs, the patient's warfarin dosage was adjusted to reach the target INR values when reused the two drugs. According to the literature analysis, when combination between gefitinib or epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) with warfarin, some patients' INR values increased, and also the risks of bleeding. CONCLUSION Concomitant administration of EGFR-TKI and warfarin, closer INR monitoring ang dose adjustments of warfarin may be necessary when EGFR-TKI initiated and discontinued. |
| Key words: gefitinib warfarin epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) INR drug interaction |
